Changes over a Decade in Psychotropic Prescribing for People with Intellectual Disabilities: Prospective Cohort Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2020 Sep 11

PMID 32912946

Citations 5

Authors

Angela Henderson

Paula McSkimming

Deborah Kinnear

Colin McCowan

Alasdair McIntosh

Linda Allan

Sally-Ann Cooper

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate psychotropic prescribing in the intellectual disabilities population over 10 years, and associated mental ill health diagnoses.

Design: Comparison of cross-sectional data in 2002-2004 (T1) and 2014 (T2). Longitudinal cohort study with detailed health assessments at T1 and record linkage to T2 prescribing data.

Setting: General community.

Participants: 1190 adults with intellectual disabilities in T1 compared with 3906 adults with intellectual disabilities in T2. 545/1190 adults with intellectual disabilities in T1 were alive and their records linked to T2 prescribing data.

Main Outcome Measures: Encashed regular and as-required psychotropic prescriptions.

Results: 50.7% (603/1190) of adults in T1 and 48.2% (1881/3906) in T2 were prescribed at least one psychotropic; antipsychotics: 24.5% (292/1190) in T1 and 16.7% (653/3906) in T2; antidepressants: 11.2% (133/1190) in T1 and 19.1% (746/3906) in T2. 21.2% (62/292) prescribed antipsychotics in T1 had psychosis or bipolar disorder, 33.2% (97/292) had no mental ill health or problem behaviours, 20.6% (60/292) had problem behaviours but no psychosis or bipolar disorder. Psychotropics increased from 47.0% (256/545) in T1 to 57.8% (315/545) in T2 (p<0.001): antipsychotics did not change (OR 1.18; 95% CI 0.87 to 1.60; p=0.280), there was an increase for antidepressants (OR 2.80; 95% CI 1.96 to 4.00; p<0.001), hypnotics/anxiolytics (OR 2.19; 95% CI 1.34 to 3.61; p=0.002), and antiepileptics (OR 1.40; 95% CI 1.06 to 1.84; p=0.017). Antipsychotic prescribing increased for people with problem behaviours in T1 (OR 6.45; 95% CI 4.41 to 9.45; p<0.001), more so than for people with other mental ill health in T1 (OR 4.11; 95% CI 2.76 to 6.11; p<0.001).

Conclusions: Despite concerns about antipsychotic prescribing and guidelines recommending their withdrawal, it appears that while fewer antipsychotic prescriptions were initiated by T2 than in T1, people were not withdrawn from them once commenced. People with problem behaviours had increased prescribing. There was also a striking increase in antidepressant prescriptions. Adults with intellectual disabilities need frequent and careful medication reviews.

Citing Articles

A Scoping Review of the Intersectionality of Autism and Intellectual and Developmental Disability with Social Inequity on Diagnosis and Treatment of Youth.

Weiss M, Daniolos P, Coughlin K, Mulvaney-Day N, Cook B, Rosenblum D J Child Adolesc Psychopharmacol. 2024; 34(7):292-301.

PMID: 38957953 PMC: 11807874. DOI: 10.1089/cap.2023.0058.

Neuroleptic malignant syndrome and serotonin syndrome: a comparative bibliometric analysis.

Sweileh W Orphanet J Rare Dis. 2024; 19(1):221.

PMID: 38825678 PMC: 11145872. DOI: 10.1186/s13023-024-03227-5.

Discordance Between Psychiatric Diagnoses and Medication Use in Children and Adults With Autism Presenting in Crisis.

Bartel R, Knight J, Worsham W, Bilder D Focus (Am Psychiatr Publ). 2024; 22(2):150-161.

PMID: 38680982 PMC: 11046722. DOI: 10.1176/appi.focus.20230027.

Psychotropic medicines' prevalence, patterns and effects on cognitive and physical function in older adults with intellectual disability in Ireland: longitudinal cohort study, 2009-2020.

Odalovic M, Gorman A, Paul A, McCallion P, Burke E, Maclachlan M BJPsych Open. 2024; 10(2):e39.

PMID: 38297892 PMC: 10897684. DOI: 10.1192/bjo.2023.607.

A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study.

Laura Ward M, Cooper S, Henderson A, Stanley B, Greenlaw N, Pacitti C Ann Gen Psychiatry. 2022; 21(1):41.

PMID: 36309752 PMC: 9617313. DOI: 10.1186/s12991-022-00418-x.

References

Lunsky Y, Khuu W, Tadrous M, Vigod S, Cobigo V, Gomes T . Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. Can J Psychiatry. 2017; 63(6):361-369. PMC: 5971404. DOI: 10.1177/0706743717727240. View

Lockhart P, Guthrie B . Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract. 2011; 61(590):e565-72. PMC: 3162179. DOI: 10.3399/bjgp11X593848. View

Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M . Data Resource Profile: The Scottish National Prescribing Information System (PIS). Int J Epidemiol. 2016; 45(3):714-715f. PMC: 5005947. DOI: 10.1093/ije/dyw060. View

Munoz-Arroyo R, Sutton M, Morrison J . Exploring potential explanations for the increase in antidepressant prescribing in Scotland using secondary analyses of routine data. Br J Gen Pract. 2006; 56(527):423-8. PMC: 1839016. View

Song M, Ware R, Doan T, Harley D . Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: a cohort study. J Intellect Disabil Res. 2019; 64(1):45-56. DOI: 10.1111/jir.12685. View

Tyrer P, Cooper S, Hassiotis A . Drug treatments in people with intellectual disability and challenging behaviour. BMJ. 2014; 349:g4323. DOI: 10.1136/bmj.g4323. View

Hollinghurst S, Kessler D, Peters T, Gunnell D . Opportunity cost of antidepressant prescribing in England: analysis of routine data. BMJ. 2005; 330(7498):999-1000. PMC: 557146. DOI: 10.1136/bmj.38377.715799.F7. View

Tsiouris J, Kim S, Brown W, Pettinger J, Cohen I . Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study. J Autism Dev Disord. 2012; 43(3):719-31. DOI: 10.1007/s10803-012-1617-6. View

ODwyer C, McCallion P, Henman M, McCarron M, OLeary E, Burke E . Prevalence and patterns of antipsychotic use and their associations with mental health and problem behaviours among older adults with intellectual disabilities. J Appl Res Intellect Disabil. 2019; 32(4):981-993. DOI: 10.1111/jar.12591. View

10.

Robertson J, Emerson E, Gregory N, Hatton C, Kessissoglou S, Hallam A . Receipt of psychotropic medication by people with intellectual disability in residential settings. J Intellect Disabil Res. 2000; 44 ( Pt 6):666-76. DOI: 10.1046/j.1365-2788.2000.00307.x. View

11.

Scheifes A, Walraven S, Stolker J, Nijman H, Egberts T, Heerdink E . Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Res Dev Disabil. 2015; 49-50:13-21. DOI: 10.1016/j.ridd.2015.11.017. View

12.

Glassman A, BIGGER Jr J . Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001; 158(11):1774-82. DOI: 10.1176/appi.ajp.158.11.1774. View

13.

de Kuijper G, Hoekstra P, Visser F, Scholte F, Penning C, Evenhuis H . Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription. J Intellect Disabil Res. 2010; 54(7):659-67. DOI: 10.1111/j.1365-2788.2010.01275.x. View

14.

Sultan R, Wang S, Crystal S, Olfson M . Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder. JAMA Netw Open. 2019; 2(7):e197850. PMC: 6661708. DOI: 10.1001/jamanetworkopen.2019.7850. View

15.

Sultan R, Correll C, Schoenbaum M, King M, Walkup J, Olfson M . National Patterns of Commonly Prescribed Psychotropic Medications to Young People. J Child Adolesc Psychopharmacol. 2018; 28(3):158-165. PMC: 5905871. DOI: 10.1089/cap.2017.0077. View

16.

McNamara R, Randell E, Gillespie D, Wood F, Felce D, Romeo R . A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities. Health Technol Assess. 2017; 21(47):1-92. PMC: 5592429. DOI: 10.3310/hta21470. View

17.

Olfson M, King M, Schoenbaum M . Treatment of Young People With Antipsychotic Medications in the United States. JAMA Psychiatry. 2015; 72(9):867-74. DOI: 10.1001/jamapsychiatry.2015.0500. View

18.

Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L . Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. BMJ. 2015; 351:h4326. PMC: 4556752. DOI: 10.1136/bmj.h4326. View

19.

Bowring D, Totsika V, Hastings R, Toogood S, McMahon M . Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study. J Intellect Disabil Res. 2017; 61(6):604-617. DOI: 10.1111/jir.12359. View

20.

SPARROW S, Cicchetti D . Diagnostic uses of the Vineland Adaptive Behavior Scales. J Pediatr Psychol. 1985; 10(2):215-25. DOI: 10.1093/jpepsy/10.2.215. View